伊普塔科潘在C5阻塞耐火性非典型血溶性尿素性综合征与相关的卡斯特曼病:病例报告
Matthew D Nguyen1,2, Stefan Ciurea3, Sheetal Desai4
1Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
BMC nephrology
|October 24, 2025
概括
本案例研究详细介绍了伊普塔科潘在非典型溶血性尿素性综合征 (aHUS) 和补充介导的血栓性微血管病变 (CMTMA) 的首次使用情况. 它还强调了与Castleman一起用于aHUS/CMTMA的第一个双重疗法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 非典型的血溶性尿素综合征 (aHUS) 是一种严重的疾病,源于补体系统突变.
- 补充介导的血栓性微血管病变 (CMTMA) 可以模仿aHUS,使诊断和治疗复杂化.
- 卡斯特曼病被确定为一个潜在的模仿 aHUS.
研究的目的:
- 报告B因子抑制对补充介导的血栓性微血管病变 (CMTMA) 患者的首次使用.
- 用伊普塔科潘和双重组合治疗描述aHUS/CMTMA的成功治疗.
- 为了记录一个同时患有aHUS/CMTMA和卡斯特曼病的患者的管理.
主要方法:
- 一名怀疑有aHUS的21岁男性患者初步接受了eculizumab治疗,随后接受了ravulizumab治疗.
- 由于部分反应和随后的爆发,Iptacopan的同情使用得到批准并被管理.
- 双重组合治疗涉及C5阻塞抑制剂,B因子抑制剂和西尔图西马布,用于复发的aHUS和并发的卡斯特曼病.
主要成果:
- 患者最初对eculizumab有部分反应,随后对ravulizumab有完全反应.
- 伊普塔科潘的使用导致了血细胞计数的恢复,微血管病性血液溶解性贫血的停止,以及急性损伤的解决.
- 双重治疗导致持续缓解,允许停止代疗法.
结论:
- 这一案例是Iptacopan在HUS/CMTMA的首次记录使用.
- 这也标志着在美国首次使用联合eculizumab和B因子抑制治疗卡斯特曼病的aHUS/CMTMA.
- 这些发现强调了针对复杂补充介导疾病的新型治疗策略的潜力.
相关概念视频
01:19Allosteric Proteins-ATCase
4.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
4.9K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
694
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
694
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
859
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
859